vs
Alector, Inc.（ALEC）与NEUROCRINE BIOSCIENCES INC（NBIX）财务数据对比。点击上方公司名可切换其他公司
NEUROCRINE BIOSCIENCES INC的季度营收约是Alector, Inc.的129.1倍（$805.5M vs $6.2M）。NEUROCRINE BIOSCIENCES INC净利率更高（19.1% vs -597.5%，领先616.6%）。NEUROCRINE BIOSCIENCES INC同比增速更快（28.3% vs -88.5%）。过去两年NEUROCRINE BIOSCIENCES INC的营收复合增速更高（25.0% vs -37.4%）
Alector是一家临床阶段生物制药企业，专注于神经退行性疾病的免疫疗法研发，管线覆盖阿尔茨海默病、额颞叶痴呆、帕金森病等未被满足的医疗需求，主要在美国运营，与全球药企合作推进候选药物的临床试验。
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
ALEC vs NBIX — 直观对比
营收规模更大
NBIX
是对方的129.1倍
$6.2M
营收增速更快
NBIX
高出116.8%
-88.5%
净利率更高
NBIX
高出616.6%
-597.5%
两年增速更快
NBIX
近两年复合增速
-37.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $6.2M | $805.5M |
| 净利润 | $-37.3M | $153.7M |
| 毛利率 | — | 97.8% |
| 营业利润率 | -634.4% | 26.2% |
| 净利率 | -597.5% | 19.1% |
| 营收同比 | -88.5% | 28.3% |
| 净利润同比 | -1696.9% | 49.1% |
| 每股收益（稀释后） | $-0.34 | $1.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALECNBIX
| Q4 25 | $6.2M | $805.5M | ||
| Q3 25 | $3.3M | $794.9M | ||
| Q2 25 | $7.9M | $687.5M | ||
| Q1 25 | $3.7M | $572.6M | ||
| Q4 24 | $54.2M | $627.7M | ||
| Q3 24 | $15.3M | $622.1M | ||
| Q2 24 | $15.1M | $590.2M | ||
| Q1 24 | $15.9M | $515.3M |
净利润ALECNBIX
| Q4 25 | $-37.3M | $153.7M | ||
| Q3 25 | $-34.7M | $209.5M | ||
| Q2 25 | $-30.5M | $107.5M | ||
| Q1 25 | $-40.5M | $7.9M | ||
| Q4 24 | $-2.1M | $103.1M | ||
| Q3 24 | $-42.2M | $129.8M | ||
| Q2 24 | $-38.7M | $65.0M | ||
| Q1 24 | $-36.1M | $43.4M |
毛利率ALECNBIX
| Q4 25 | — | 97.8% | ||
| Q3 25 | — | 98.2% | ||
| Q2 25 | — | 98.4% | ||
| Q1 25 | — | 98.4% | ||
| Q4 24 | — | 98.5% | ||
| Q3 24 | — | 98.7% | ||
| Q2 24 | — | 98.4% | ||
| Q1 24 | — | 98.5% |
营业利润率ALECNBIX
| Q4 25 | -634.4% | 26.2% | ||
| Q3 25 | -1153.6% | 30.1% | ||
| Q2 25 | -433.6% | 21.2% | ||
| Q1 25 | -1216.5% | 4.1% | ||
| Q4 24 | -13.4% | 22.6% | ||
| Q3 24 | -315.7% | 29.5% | ||
| Q2 24 | -302.4% | 24.6% | ||
| Q1 24 | -275.0% | 19.3% |
净利率ALECNBIX
| Q4 25 | -597.5% | 19.1% | ||
| Q3 25 | -1063.4% | 26.4% | ||
| Q2 25 | -387.7% | 15.6% | ||
| Q1 25 | -1101.6% | 1.4% | ||
| Q4 24 | -3.8% | 16.4% | ||
| Q3 24 | -275.2% | 20.9% | ||
| Q2 24 | -256.4% | 11.0% | ||
| Q1 24 | -227.0% | 8.4% |
每股收益（稀释后）ALECNBIX
| Q4 25 | $-0.34 | $1.49 | ||
| Q3 25 | $-0.34 | $2.04 | ||
| Q2 25 | $-0.30 | $1.06 | ||
| Q1 25 | $-0.41 | $0.08 | ||
| Q4 24 | $-0.02 | $1.00 | ||
| Q3 24 | $-0.43 | $1.24 | ||
| Q2 24 | $-0.40 | $0.63 | ||
| Q1 24 | $-0.38 | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $256.0M | $713.0M |
| 总债务越低越好 | $10.0M | — |
| 股东权益账面价值 | $30.6M | $3.3B |
| 总资产 | $293.2M | $4.6B |
| 负债/权益比越低杠杆越低 | 0.33× | — |
8季度趋势，按日历期对齐
现金及短期投资ALECNBIX
| Q4 25 | $256.0M | $713.0M | ||
| Q3 25 | $291.1M | $340.2M | ||
| Q2 25 | $307.3M | $264.0M | ||
| Q1 25 | $354.6M | $194.1M | ||
| Q4 24 | $413.4M | $233.0M | ||
| Q3 24 | $457.2M | $349.1M | ||
| Q2 24 | $503.3M | $139.7M | ||
| Q1 24 | $562.1M | $396.3M |
总债务ALECNBIX
| Q4 25 | $10.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ALECNBIX
| Q4 25 | $30.6M | $3.3B | ||
| Q3 25 | $57.7M | $3.0B | ||
| Q2 25 | $71.2M | $2.7B | ||
| Q1 25 | $94.6M | $2.5B | ||
| Q4 24 | $126.8M | $2.6B | ||
| Q3 24 | $118.9M | $2.7B | ||
| Q2 24 | $150.6M | $2.5B | ||
| Q1 24 | $178.9M | $2.4B |
总资产ALECNBIX
| Q4 25 | $293.2M | $4.6B | ||
| Q3 25 | $335.3M | $4.3B | ||
| Q2 25 | $356.4M | $3.9B | ||
| Q1 25 | $408.3M | $3.7B | ||
| Q4 24 | $468.3M | $3.7B | ||
| Q3 24 | $516.0M | $3.5B | ||
| Q2 24 | $570.7M | $3.3B | ||
| Q1 24 | $635.5M | $3.5B |
负债/权益比ALECNBIX
| Q4 25 | 0.33× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.08× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-41.7M | $388.4M |
| 自由现金流经营现金流 - 资本支出 | — | $386.0M |
| 自由现金流率自由现金流/营收 | — | 47.9% |
| 资本支出强度资本支出/营收 | 0.0% | 0.3% |
| 现金转化率经营现金流/净利润 | — | 2.53× |
| 过去12个月自由现金流最近4个季度 | — | $743.9M |
8季度趋势，按日历期对齐
经营现金流ALECNBIX
| Q4 25 | $-41.7M | $388.4M | ||
| Q3 25 | $-32.5M | $227.5M | ||
| Q2 25 | $-49.0M | $102.0M | ||
| Q1 25 | $-60.8M | $64.8M | ||
| Q4 24 | $-55.0M | $242.5M | ||
| Q3 24 | $-50.7M | $158.0M | ||
| Q2 24 | $-62.8M | $64.6M | ||
| Q1 24 | $-61.3M | $130.3M |
自由现金流ALECNBIX
| Q4 25 | — | $386.0M | ||
| Q3 25 | $-32.5M | $214.3M | ||
| Q2 25 | $-49.1M | $89.5M | ||
| Q1 25 | $-60.8M | $54.1M | ||
| Q4 24 | $-55.2M | $235.2M | ||
| Q3 24 | $-50.9M | $149.9M | ||
| Q2 24 | $-63.1M | $53.0M | ||
| Q1 24 | $-61.9M | $119.1M |
自由现金流率ALECNBIX
| Q4 25 | — | 47.9% | ||
| Q3 25 | -997.6% | 27.0% | ||
| Q2 25 | -623.0% | 13.0% | ||
| Q1 25 | -1655.0% | 9.4% | ||
| Q4 24 | -101.8% | 37.5% | ||
| Q3 24 | -332.1% | 24.1% | ||
| Q2 24 | -418.6% | 9.0% | ||
| Q1 24 | -389.3% | 23.1% |
资本支出强度ALECNBIX
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.3% | 1.7% | ||
| Q2 25 | 0.1% | 1.8% | ||
| Q1 25 | 0.5% | 1.9% | ||
| Q4 24 | 0.3% | 1.2% | ||
| Q3 24 | 1.4% | 1.3% | ||
| Q2 24 | 2.2% | 2.0% | ||
| Q1 24 | 3.4% | 2.2% |
现金转化率ALECNBIX
| Q4 25 | — | 2.53× | ||
| Q3 25 | — | 1.09× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | — | 8.20× | ||
| Q4 24 | — | 2.35× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 0.99× | ||
| Q1 24 | — | 3.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALEC
暂无分部数据
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
